Edgar Filing: BIOGEN IDEC INC. - Form 4

BIOGEN IDEC INC. Form 4 October 02, 2013 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).									3235-0287 January 31, 2005 verage 's per		
(Print or Type	Responses)										
SCANGOS GEORGE A Symbol				r Name and N IDEC 1			ing	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (M	/liddle)	3. Date of Earliest Transaction					(Check	eck all applicable)		
				onth/Day/Year) /01/2013				_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
				nendment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tabl	e I - Non-D) erivative	Secu	rities Aca	uired, Disposed of,	or Beneficial	v Owned	
1.Title of Security (Instr. 3)		action Date 2A. Deemed			4. Securi n(A) or Di (Instr. 3, Amount	ties A ispose	cquired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature of Ownership Indirect Form: Direct Beneficial (D) or Ownership Indirect (I) (Instr. 4) (Instr. 4)		
Common Stock	10/01/2013			Code V $S^{(1)}$	1,127	D	\$ 242.85	42,395	D		
Common Stock	10/01/2013			S <u>(1)</u>	1,112	D	\$ 242.85	41,283	D		
Common Stock								5,378	I	by Trust	
Common Stock								5,378	Ι	by Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: BIOGEN IDEC INC. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
SCANGOS GEORGE A BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493	Х		Chief Executive Officer					
Signatures								

/s/ Matthew S. Gilman, Attorney in Fact for George A. Scangos <u>**</u>Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.